SpringWorks stock jumps as Merck nears M&A deal (SWTX:NASDAQ) - Seeking Alpha
2 days ago • Google News
SpringWorks Therapeutics Inc (SWTX)
US$ 44.72-0.57%
Price Chart
Key Statistics
Market Cap
$ 3.37B
P/E Ratio
0.00
Revenue (TTM)
$ 191.59M
Volume
7.71M
52W High
$ 62.00
52W Low
$ 28.21
Dividend Yield
0.00%
Beta
0.79
Technicals
50-Day MA
47.4298
200-Day MA
39.3667
52 Week High
62
52 Week Low
28.21
About SWTX
SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare dise.
Employees
368
Headquarters
Stamford, CT
CEO
Mr. Saqib Islam J.D.
Latest News
EU Regulators Set to Rule on SpringWorks' Breakthrough Desmoid Tumor Treatment in Q2 2025 - Stock Titan
15 hours ago • Google News
SpringWorks Therapeutics (SWTX) Awaits EMA's Decision on Nirogac - GuruFocus
5 hours ago • Google News
Top Gainers
Symbol/Name
LTP
% Chg
Top Losers
Symbol/Name
LTP
% Chg